Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Non-Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Pre-Surgical Therapy in Treatment-Naive Subjects With Stage IA or IB, Resectable Non Small Cell Lung Cancer (NSCLC).

Next Previous
X
Search
Trial Profile

A Phase II, Non-Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Pre-Surgical Therapy in Treatment-Naive Subjects With Stage IA or IB, Resectable Non Small Cell Lung Cancer (NSCLC).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors GSK

    • Most Recent Events

    • 11 Aug 2009 Actual patient number (35) added as reported by ClinicalTrials.gov.
    • 15 Sep 2008 Data presented at ESMO 2008 according to GlaxoSmithKline media release.
    • 03 Jun 2008 Primary endpoint met in 87% of patients. Final results presented at the American Society of Clinical Oncology (ASCO) 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top